Multimodal Treatment Strategy for Locally Advanced Breast Cancer

A. De Matteis, M. Montella, M. Iannuzzo, M. R. De Marco, G. Landi, V. Labonia, P. Frezza, M. Cerra, P. Oliviero, G. D'Aiuto

Research output: Contribution to journalArticle

Abstract

Between 1990 and 1995, 87 patients with locally advanced breast cancer were treated with initial chemotherapy consisting of 3-4 cycles of epirubicin and then with surgery, radiotherapy and chemotherapy. All patients with positive or unknown estrogen receptor status were administered tamoxifen. A complete response was observed in 9 patients and a partial response in 64. At a mean follow-up of 29.22 months, 25 patients had died of metastatic disease, and 48 patients are disease-free. 54% patients are alive at 5 years. Statistical analysis confirmed that neither age, menopausal status, size of the primary tumor nor histology seemed to influence the Disease Free and Overall Survival. Improved survival was observed in patients with negative lymph nodes and positive receptor status. The presence of a positive receptor status may be correlated with conserved integrity of hormone sensitivity and with a good response to the hormone therapy.

Original languageEnglish
Pages (from-to)476-483
Number of pages8
JournalJournal of Chemotherapy
Volume10
Issue number6
Publication statusPublished - 1998

Fingerprint

Combined Modality Therapy
Breast Neoplasms
Hormones
Drug Therapy
Epirubicin
Tamoxifen
Estrogen Receptors
Disease-Free Survival
Histology
Radiotherapy
Lymph Nodes
Survival

Keywords

  • Breast cancer
  • Estrogen receptors
  • Locally advanced breast cancer
  • Neoadjuvant chemotherapy
  • Tamoxifen

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Cite this

De Matteis, A., Montella, M., Iannuzzo, M., De Marco, M. R., Landi, G., Labonia, V., ... D'Aiuto, G. (1998). Multimodal Treatment Strategy for Locally Advanced Breast Cancer. Journal of Chemotherapy, 10(6), 476-483.

Multimodal Treatment Strategy for Locally Advanced Breast Cancer. / De Matteis, A.; Montella, M.; Iannuzzo, M.; De Marco, M. R.; Landi, G.; Labonia, V.; Frezza, P.; Cerra, M.; Oliviero, P.; D'Aiuto, G.

In: Journal of Chemotherapy, Vol. 10, No. 6, 1998, p. 476-483.

Research output: Contribution to journalArticle

De Matteis, A, Montella, M, Iannuzzo, M, De Marco, MR, Landi, G, Labonia, V, Frezza, P, Cerra, M, Oliviero, P & D'Aiuto, G 1998, 'Multimodal Treatment Strategy for Locally Advanced Breast Cancer', Journal of Chemotherapy, vol. 10, no. 6, pp. 476-483.
De Matteis A, Montella M, Iannuzzo M, De Marco MR, Landi G, Labonia V et al. Multimodal Treatment Strategy for Locally Advanced Breast Cancer. Journal of Chemotherapy. 1998;10(6):476-483.
De Matteis, A. ; Montella, M. ; Iannuzzo, M. ; De Marco, M. R. ; Landi, G. ; Labonia, V. ; Frezza, P. ; Cerra, M. ; Oliviero, P. ; D'Aiuto, G. / Multimodal Treatment Strategy for Locally Advanced Breast Cancer. In: Journal of Chemotherapy. 1998 ; Vol. 10, No. 6. pp. 476-483.
@article{bf64bb9c381e4bc2a1fabe5a899c83d4,
title = "Multimodal Treatment Strategy for Locally Advanced Breast Cancer",
abstract = "Between 1990 and 1995, 87 patients with locally advanced breast cancer were treated with initial chemotherapy consisting of 3-4 cycles of epirubicin and then with surgery, radiotherapy and chemotherapy. All patients with positive or unknown estrogen receptor status were administered tamoxifen. A complete response was observed in 9 patients and a partial response in 64. At a mean follow-up of 29.22 months, 25 patients had died of metastatic disease, and 48 patients are disease-free. 54{\%} patients are alive at 5 years. Statistical analysis confirmed that neither age, menopausal status, size of the primary tumor nor histology seemed to influence the Disease Free and Overall Survival. Improved survival was observed in patients with negative lymph nodes and positive receptor status. The presence of a positive receptor status may be correlated with conserved integrity of hormone sensitivity and with a good response to the hormone therapy.",
keywords = "Breast cancer, Estrogen receptors, Locally advanced breast cancer, Neoadjuvant chemotherapy, Tamoxifen",
author = "{De Matteis}, A. and M. Montella and M. Iannuzzo and {De Marco}, {M. R.} and G. Landi and V. Labonia and P. Frezza and M. Cerra and P. Oliviero and G. D'Aiuto",
year = "1998",
language = "English",
volume = "10",
pages = "476--483",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "6",

}

TY - JOUR

T1 - Multimodal Treatment Strategy for Locally Advanced Breast Cancer

AU - De Matteis, A.

AU - Montella, M.

AU - Iannuzzo, M.

AU - De Marco, M. R.

AU - Landi, G.

AU - Labonia, V.

AU - Frezza, P.

AU - Cerra, M.

AU - Oliviero, P.

AU - D'Aiuto, G.

PY - 1998

Y1 - 1998

N2 - Between 1990 and 1995, 87 patients with locally advanced breast cancer were treated with initial chemotherapy consisting of 3-4 cycles of epirubicin and then with surgery, radiotherapy and chemotherapy. All patients with positive or unknown estrogen receptor status were administered tamoxifen. A complete response was observed in 9 patients and a partial response in 64. At a mean follow-up of 29.22 months, 25 patients had died of metastatic disease, and 48 patients are disease-free. 54% patients are alive at 5 years. Statistical analysis confirmed that neither age, menopausal status, size of the primary tumor nor histology seemed to influence the Disease Free and Overall Survival. Improved survival was observed in patients with negative lymph nodes and positive receptor status. The presence of a positive receptor status may be correlated with conserved integrity of hormone sensitivity and with a good response to the hormone therapy.

AB - Between 1990 and 1995, 87 patients with locally advanced breast cancer were treated with initial chemotherapy consisting of 3-4 cycles of epirubicin and then with surgery, radiotherapy and chemotherapy. All patients with positive or unknown estrogen receptor status were administered tamoxifen. A complete response was observed in 9 patients and a partial response in 64. At a mean follow-up of 29.22 months, 25 patients had died of metastatic disease, and 48 patients are disease-free. 54% patients are alive at 5 years. Statistical analysis confirmed that neither age, menopausal status, size of the primary tumor nor histology seemed to influence the Disease Free and Overall Survival. Improved survival was observed in patients with negative lymph nodes and positive receptor status. The presence of a positive receptor status may be correlated with conserved integrity of hormone sensitivity and with a good response to the hormone therapy.

KW - Breast cancer

KW - Estrogen receptors

KW - Locally advanced breast cancer

KW - Neoadjuvant chemotherapy

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0032239074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032239074&partnerID=8YFLogxK

M3 - Article

C2 - 9876057

AN - SCOPUS:0032239074

VL - 10

SP - 476

EP - 483

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 6

ER -